Business Context and Reporting Period
This Form 6-K filing by Ascendis Pharma A/S, dated January 8, 2026, reports topline results from Week 52 of the COACH Phase 2 clinical trial. The trial evaluates the combination therapy of once-weekly TransCon CNP (navepegritide) and once-weekly TransCon hGH (lonapegsomatropin) in children aged 2 to 11 with achondroplasia.
Key Financial Metrics
The filing text does not provide specific financial data, including revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on clinical trial outcomes and regulatory status.
Material Changes and Clinical Results
The filing details significant clinical efficacy data from the COACH trial at Week 52:
- TransCon CNP Treatment-Naïve Cohort (N=12): Mean annualized growth velocity (AGV) was 8.80 cm/year, representing a tripling of efficacy compared to TransCon CNP monotherapy. Mean ACH height Z-score improved by +1.02.
- TransCon CNP-Treated Cohort (N=9): Mean AGV was 8.42 cm/year, an increase of 3.28 cm/year from baseline. Mean ACH height Z-score improved from 1.28 to 2.15 (+0.86).
- Growth Milestones: After 52 weeks, children on combination therapy exceeded the 97th-percentile AGV of average-stature children. Arm span improved beyond the 84th-percentile for children with achondroplasia.
- Safety: Combination therapy was generally well-tolerated with mild treatment-emergent adverse events (TEAEs) and low incidence of injection site reactions. Bone age remained consistent with chronological age.
Guidance, Outlook, and Risks
Regulatory Status: TransCon CNP is under Priority Review by the FDA with a PDUFA target action date of February 28, 2026, and is also under review by the European Medicines Agency as a monotherapy. In Q4 2025, the company submitted a protocol and held an end-of-Phase 2 meeting with the FDA regarding a Phase 3 trial for the combination therapy.
Risks and Contingencies: The filing includes standard forward-looking statement disclaimers. Key risks include regulatory approval delays, clinical development uncertainties, manufacturing dependencies, supply chain issues, market acceptance, pricing challenges, and geopolitical factors. The company notes that actual results may differ materially from projections.
Investor Verification Checklist
- Verify the FDA PDUFA target action date of February 28, 2026, for TransCon CNP monotherapy approval.
- Confirm the design and enrollment status of the upcoming Phase 3 trial for combination therapy following the Q4 2025 FDA meeting.
- Monitor safety data for long-term combination therapy beyond the 52-week mark.
- Review the company's most recent Form 20-F (filed February 12, 2025) for detailed financial position and cash runway.
- Assess potential impacts of regulatory decisions on the commercialization timeline for SKYTROFA and the investigational combination therapy.